+8615710194249

About Us

Leadership Team

Guo Zhijun

Head of Production

Mr. Zhijun Guo is the Chief Technology Officer at Immorna and Co-founder of the Immorna family of companies. He has more than 30 years of scientific and leadership experience in the infectious disease vaccine industry. Prior to co-founding Immorna with Dr. Zihao Wang, Mr. Guo was Associate General Manager at King-cell Biotechnology (Shanghai) where he established the full quality system to support the drug lifecycle management as a whole, and led the GMP compliance taskforce. Prior to King-cell, Mr. Guo worked for more than 15 years at Tianyuan Biopharmaceutical Co. Ltd. (part of Novartis Vaccines and Diagnostics, then GSK Vaccines) with increasing technical and leadership roles. He was Head of the Manufacturing Science & Technology function before he left GSK Vaccines. Mr. Guo is a well-recognized expert in CMC development, tech transfer, process validation, and GMP manufacturing. He also has extensive experience in regulatory submissions for all phases of vaccine clinical trials and commercial product registration. He led the successful registration of Novartis and GSK rabies, human papillomavirus (HPV) and quadrivalent influenza vaccines. Mr. Guo holds an MBA degree from the University of Montpellier in France.

Cai Ji

Process Leader

Mr. Cai Ji, Director of Manufacturing Science and Technology Department, is responsible for the GMP production of the company's clinical filing projects and clinical study drugs. He has nearly 10 years of experience in downstream purification process development, GMP production and project management. As the project leader of Afamelanotide, he was responsible for the whole process from process development to NDA filing. Worked as a key participant in the full process from process development to NDA filing in the EU for the drug API Bulevirtide, a drug pipeline that was later acquired by Gilead. During his tenure, as a project leader, he was responsible for the process development and manufacturing of 10~20 IND PhaseI~PhaseII drugs per year. As a GMP Production Director, he has managed nearly 100 employees under the production department and has many years of experience in people management and project management. Since joining Imona, he has completed the GMP manufacturing of four FDA IND projects and was responsible for writing some of the filings. She has also completed one IND filing and two IIT clinical drug manufacturing projects in China.

Min Wang

Analytical Method Development & QC Leader

Wang Min is currently responsible for analytical method development and quality control at Immorna. He previously worked at Hongyun Huaning (Hangzhou) Biopharmaceutical Co., Ltd., gaining 10 years of experience in the development of analytical methods and quality control for biopharmaceuticals. As a key team member, he participated in the GLP-1 long-acting drug, antibody drug, and several non-self-replicating mRNA and self-replicating srRNA projects, contributing to clinical submissions and pharmaceutical research of clinical trials in China.

Marcin Bugno

Vice President, Head of RNA Development

Dr. Marcin Bugno is the Vice President, Head of RNA Development. He has 20 years of R&D experience in academia, biotech and large pharma companies. Prior to joining Immorna, Dr. Bugno served as Senior Director, Analytical and Process Development at Istari Oncology, Director of Technical R&D, Drug Substance at GSK Vaccines and manager of process development and tech transfer teams at Novartis Vaccines and Diagnostics. He has experience in analytical and process development for recombinant viral products, protein biologics, and mRNA vaccines; including RNA drug substance process development and manufacturing support for the first-in-human GSK RNA vaccine program as well as cell line and process development for GSK’s Arexvy, the licensed respiratory syncytial virus (RSV) vaccine. Dr. Bugno published 18 research papers and 3 patents in the field of process science, cell biology, virology, biochemistry and molecular biology.